Floatz logo

Mirvetuximab Soravtansine

Folate Receptor Alpha Positive

Ohio State University Comprehensive Cancer Centerantibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Folate Receptor Alpha Positive cohort.

Asset / SponsorPhaseRating
Rucaparib
Ohio State University Comprehensive Cancer Center
Phase 1CC
5-azacytidine
Ohio State University Comprehensive Cancer Center
Phase 1CC

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →